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ABSTRACT 
 
A Simple Way to Generate Cell-Specific Knockdown Mice by Double 
Transfection of Cre/loxP Lentiviral Vector 
 
Bo-Young Nam 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Shin-Wook Kang) 
 
 
Background: In case of eternal gene manipulation, there can be limits in 
figuring out functions of genes that are temporarily activated at diseases. To 
overcome such problems, cell-specific and tissue-specific gene technology was 
recently developed and has been greatly helpful for understanding functions of 
genes of persons suffering from various diseases. It is one of organism-specific 
gene expression manipulation systems widely utilized for conditional gene 
knockout in selective cell or tissue by Cre, a site-specific recombinase. To 
develop gene manipulation animals, Cre genetically modified animals are 
 2 
 
established through fertilization and crossbreeding after cell-specific Cre genes 
are injected to embryonic stem cells. However, there are limits to use it in terms 
of time and money. On the other hand, lentivirus-based gene delivery system, 
gene has incorporated into host chromosomes and continuously expressed for a 
long time, therefore, genes can be effectively conveyed to already differentiated 
and non-proliferating cells such as nerve cells. 
 
Purpose: In this study, I invented a simple way to knockdown a specific gene in 
a cell-specific pattern in adult mice by lentivirus-assisted transfer of shRNA. 
 
Methods: In vitro, for lentiviral transfection, 4 × 105 TU of the lentivirus 
suspension containing LV-Hoxb7 Cre and/or LV-shAQP3 was added to 
cultured Mouse renal collecting duct cells and mouse mesangial cells. After 48 
hr, the media were changed to routine culture media. At 72 hr after the media 
change, cells were harvested. In vivo experiments, there were three models to 
check efficiency of each virus. First, LV-Hoxb7 Cre is injected into the loxP-
EGFP mice to check efficiency of the Hoxb7 promoter. These mice were 
divided into two groups, and were injected with PBS (Con) or LV-Hoxb7 Cre. 
For the second animal experiments, Hoxb7 Cre transgenic mice were used. 
They were classified into three groups based on what was injected with PBS 
(Con), LV-loxP scr, or LV-loxP shAQP3. For the third animal experiments, male 
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C57BL6/J mice were assigned to one of the four groups, and were injected with 
PBS (Con), LV-Hoxb7 Cre, LV-loxP shAQP3, or LV-Hoxb7 Cre + LV-loxP 
shAQP3. All animals were given the selected treatment on days 0, 4, and 7 via 
hydrodynamic tail vein injection as described previously. For C57BL6/J mice 
treated with consecutive injection of LV-Hoxb7 Cre and LV-loxP shAQP3, LV-
shAQP3 was introduced on days 3, 7, and 10 after the final injection of LV-
Hoxb7 Cre. Briefly, a volume of 1 ml of PBS alone or PBS containing 4 × 108 
TU of lentivirus were injected to mice via the tail vein within 10 sec. Mice were 
sacrificed at 6-week after the first injection of PBS or lentivirus. EGFP, 
mCherry, and AQP3 protein expression in renal collecting duct cells, the kidney 
were evaluated by Western blot analysis, immunofluoresence staining, and 
AQP3 mRNA expression by real-time PCR. 
 
Results: In vitro, LV-Hoxb7 Cre, which contained Hoxb7 promoter, worked 
only in collecting duct cells due to the presence of Hoxb7 in collecting duct 
cells but not in mesangial cells. Furthermore, combined infection of collecting 
duct cells with LV-Hoxb7 Cre and LV-loxP shAQP3 significantly inhibited the 
protein expression of AQP3 along with the disappearance of EGFP protein 
expression, suggesting that LV-Hoxb7 Cre and LV-loxP shAQP3 used in the 
present study worked together effectively. 
In vivo, both EGFP and mCherry protein were completely expressed at the 
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same site, in kidney collecting duct cells of loxP-EGFP mice, where Hoxb7 
promoter was working, but not in the liver of LoxP-EGFP + LV-Hoxb7 Cre 
mice. The protein expression of EGFP in the kidney was observed in Hoxb7 Cre 
mice injected with LV-loxP scr or LV-loxP shAQP3. Furthermore, AQP3 protein 
and mRNA expression were significantly reduced in Hoxb7 Cre mice injected 
with LV-loxP shAQP3 compared to inject with PBS and LV-loxP scr. In addition, 
even though urine volume was significantly increased, urine osmolality was 
significantly decreased by 44.4% in Hoxb7 Cre + LV-loxP shAQP3 mice 
compared to the other groups. In contrast, there was no significant change in the 
protein expression of AQP3 in the colon and trachea by LV-loxP scr or LV-loxP 
shAQP3 injection in spite of demonstrable expression of EGFP protein. Finally, 
I tried to generate AQP3 knockout mice in C57BL/6J mice by consecutive 
injection of LV-Hoxb7 Cre and LV-loxP shAQP3. When LV-Hoxb7 Cre was 
introduced in these mice, the expression of mCherry protein was found only in 
the kidney collecting duct cells. Moreover, injection of LV-loxP shAQP3 
resulted in an increase in EGFP protein expression in all kidney cells except for 
collecting duct cells. However, there were no significant differences in the 
protein and mRNA expression of AQP3 in C57BL/6J mice injected with LV-
Hoxb7 Cre or LV-loxP shAQP3 alone. In contrast, when consecutive injection 
of LV-Hoxb7 Cre and LV-loxP shAQP3 was performed in these mice, AQP3 
protein and mRNA expression were significantly reduced. Even though urine 
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volume was significantly increased, urine osmolality was significantly 
decreased in LV-Hoxb7 Cre and LV-loxP shAQP3 injected mice compared to 
the other groups. Meanwhile, the protein expression of EGFP was also observed 
in the colon and trachea of C57BL/6J mice by the administration of LV-loxP 
shAQP3 with or without LV-Hoxb7 Cre, but AQP3 protein expression was not 
changed by these treatment. 
 
Conclusions: These findings suggest that double transduction of Cre- and loxP-
based lentivirus can be a simple way to generate cell-specific knockdown mice, 
and this method may also be applicable to other species. 
 
 
 
 
 
 
 
 
 
 
----------------------------------------------------------------------------------------------------------  
Key words: Cre/loxP system, lentiviral vector, renal collecting duct cell, Hoxb7, 
aquaporin-3  
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I. INTRODUCTION 
Upregulation or downregulation of certain genes is associated with the 
development and progression of most diseases. Therefore, genetically 
engineered mice with a gene overexpression or knockout have been used to 
elucidate the precise role of a specific gene in the pathogenesis of a disease1. 
Specifically, regarding a downregulated gene, transgenic mice generated by 
conventional knockout techniques using oocytes or embryonic stem (ES) cells 
have been the most commonly used approach, but these methods have some 
limitations: persistent impact of the deleted gene throughout mice ontogeny 
with a possibility to result in a lethal phenotype2 or an unexpected 
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compensatory increase in other genes3, affection of all cell types, and cost- and 
time-consuming procedure. 
To overcome some of these problems4, a number of modern technologies to 
manipulate cell- or tissue-specific genes have been developed and been 
remarkably helpful for figuring out the definite function of genes in each cell or 
tissue during the disease process. Among these, the Cre-recombinant-loxP 
system has been widely used5,6. It is one of organism-specific gene expression 
manipulation systems widely utilized for conditional gene knockout in selective 
cell or tissue by Cre, a site-specific recombinase5-8. Gene disruption appears by 
target gene flanked by the loxP rank when bacteriophage P1 Cre recombinase 
recognizes the loxP region5-7. Furthermore, this system is operative to generate 
conditional knockout mice in an inducible manner by using the tamoxifen- or 
tetracycline-based system9-11. Nevertheless an advance in genetic engineering, 
there are still several constraints such as the need of time to breed mice, a 
relatively low success rates, and a difficulty in applying to other species. In 
addition, a huge amount of money, about 100-200 thousand dollars according to 
the report of the National Institute of Health (NIH), are expected to be spent for 
implanting a cell-specific Cre gene to ES cells to develop a Cre recombinase 
animal and then to establish Cre gene recombinant animal through fertilization 
and crossbreeding. 
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In this study, I invented a simple way to knockdown a specific gene in a cell-
specific pattern in adult mice by lentivirus-assisted transfer of short hairpin 
RNA (shRNA). First, a group of collecting duct-specific aquaporin-3 (AQP3) 
knockdown mice was generated by injecting loxP-AQP3 shRNA expressing 
lentivirus (LV-loxP shAQP3) to adult homeobox B7 (Hoxb7) Cre transgenic 
mice, which expressed the Cre recombinase only in the collecting ducts under 
the control of the mouse Hoxb7 enhancer and promoter. Second, another group 
of collecting duct-specific AOP3 knockdown mice was generated by 
consecutive injection of Hoxb7-Cre expressing lentivirus (LV-Hoxb7 Cre) and 
LV-loxP shAQP3 in adult C57BL6/J mice. 
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II. MATERIALS AND METHODS 
1. Generation of loxP-AQP3 shRNA expressing lentivirus and Hoxb7-Cre 
expressing lentivirus 
According to the mouse cDNA sequence of AQP3, a small interfering RNA 
(siRNA) target sites were selected using the siRNA Selection Web Server 
(http://jura.wi.mit.edu/bioc/siRNA). In addition, a scrambled sequence was 
created as a control. The annealed oligonucleotides were inserted into the XhoI-
HpaI sites of the pSico lentiviral vector12 (Addgene, Cambridge, MA, USA). 
The PCR-positive samples were sequenced and named pSico-AQP3 shRNA and 
scrambled (scr) (Table 1). The Hoxb7 promoter was also inserted into 
the XbaII-NheI sites of the Puro-Cre empty vector13 (Addgene) (Figure 1). 
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Figure 1. Lentiviral vector designs. (A) Hoxb7-mCherry-Cre lentiviral vector and (B) 
pSico-loxP-GFP-shAQP3 lentiviral vector. (C) The mechanism of Cre/loxP system. 
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2. Lentivirus production 
Lentivirus were produced as previously described14. Human embryonic 
kidney (HEK) 293FT cells (Invitrogen, Carlsbad, CA, USA) were transfected 
with the expression vector and two helper plasmids, namely packaging plasmid 
pCMV Δ8.9 and vesicular stomatitis virus G protein plasmid, at 1, 7.5, and 
5.5 g of DNA per 150 mm plate, using the calcium phosphate method. After 
72 hr, supernatants from four plates were pooled, centrifuged at 780 g for 5 min, 
and filtered through a 0.45-m pore size filter. Next, centrifugation was 
performed at 83,000 g for 1.5 hr, and the resulting pellet was resuspended in 
100  l of phosphate-buffered saline (PBS). Lentivirus titers were determined by 
transfecting HEK 293FT cells with a dilution series of the viral suspension, and 
lentivirus samples with a titer of 4 × 108 transfection units/ml (TU) were stored 
at -80°C. 
 
3. Animal experiments 
All animal study protocols were approved by the Committee for the Care and 
Use of Laboratory Animals at Yonsei University College of Medicine in Seoul, 
Korea, and carried out in accordance with the Principles of Laboratory Animal 
Care (NIH Publication no. 85-23, revised 1985). 
For the first animal experiments, loxP-EGFP mice15 were purchased from 
Jackson Laboratories (Bar Harbor, ME, USA). They possess loxP sites on either 
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side of a membrane-targeted tdTomato (mT) cassette and express strong red 
fluorescence in all tissues and cell types. Tail or whole body epifluorescence is 
sufficient to identify mT/mG homozygotes. When bred to Cre recombinase 
expressing mice, the offsprings have the mT cassette deleted in the Cre 
expressing tissue(s), resulting in the expression of the membrane-targeted EGFP 
(mG) cassette located just downstream. These mice were divided into two 
groups, and were injected with PBS (Con) or LV-Hoxb7 Cre. 
For the second animal experiments, Hoxb7 Cre transgenic mice16 (Jackson 
Laboratories) were used. They were classified into three groups based on what 
was injected; PBS (Con), LV-loxP scr, or LV-loxP shAQP3. 
For the third animal experiments, male C57BL6/J mice (Jackson Laboratories) 
weighing 24-26 g were assigned to one of the five groups, and were injected 
with PBS (Con), LV-Hoxb7 Cre, LV-loxP shAQP3, LV-Hoxb7 Cre + LV-loxP 
scr, or LV-Hoxb7 Cre + LV-loxP shAQP3. 
All animals were given the selected treatment on days 0, 4, and 7 via 
hydrodynamic tail vein injection as described previously17. For C57BL6/J mice 
treated with consecutive injection of LV-Hoxb7 Cre and LV-loxP shAQP3, LV-
shAQP3 was introduced on days 3, 7, and 10 after the final injection of LV-
Hoxb7 Cre. Briefly, a volume of 1 ml of PBS alone or PBS containing 4 × 108 
TU of lentivirus were injected to mice via the tail vein within 10 sec. Mice were 
killed at 6-week after the first injection of PBS or lentivirus. 
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Mice were housed in a temperature-controlled room and were given free 
access to water and standard laboratory chow during the study period. 
 
4. Cell culture 
Mouse renal collecting duct cells were purchased from American Type 
Culture Collection (ATCC) (Manassas, VA, USA) (CRL-2038) and maintained 
in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's 
F12 medium with 2.5 mM L-glutamine, 15 mM HEPES, 0.5 mM sodium 
pyruvate, and 1.2 g/L sodium bicarbonate supplemented with 0.005 mM 
dexamethasone and 5% fetal bovine serum (FBS) (Invitrogen). Mouse 
mesangial cells from an SV40 transgenic mouse (MES-13) were also purchased 
from ATCC and maintained in DMEM containing 5% FBS. The cells were 
grown at 37°C in humidified 5% CO2 in air. 
For lentiviral transfection, 4 × 105 TU of the lentivirus suspension containing 
LV-Hoxb7 Cre and/or LV-shAQP3 was added to cultured cells. After 48 hr, the 
media were changed to routine culture media. At 72 hr after the media change, 
cells were harvested. The doses LV-Hoxb7 Cre and/or LV-shAQP3 used in the 
experiments were determined based on the results of preliminary experiments. 
 
5. Total RNA extraction 
Total RNA was extracted from whole kidney, colon, and trachea as previously 
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described18. Briefly, a piece of the whole kidney was snap-frozen in liquid 
nitrogen, pulverized with a mortar and pestle while frozen, and suspended in 
100 μl of RNA STAT-60 reagent (Tel-Test, Friendswood, TX, USA), which 
was lysed by freezing and thawing three times. Another 700 μl of RNA STAT-
60 reagent was then added, and the mixture was vortexed and stored for 5 min 
at room temperature. Next, 160 μl of chloroform was added and the mixture 
was shaken vigorously for 30 sec. After 3 min, the mixture was centrifuged at 
12,000 g for 15 min at 4°C and the upper aqueous phase containing the 
extracted RNA was transferred to a new tube. RNA was precipitated from the 
aqueous phase by adding 400 μl of isopropanol, and then pelleted by 
centrifugation at 12,000 g for 30 min at 4°C. The RNA precipitate was washed 
with 70% ice-cold ethanol, dried using a Speed Vac, and dissolved in DEPC-
treated distilled water. RNA yield and quality were assessed based on 
spectrophotometric measurements at wavelengths of 260 and 280 nm. Total 
RNAs from the colon and trachea, and cultured cells were extracted similarly. 
 
6. Reverse transcription 
First strand cDNA was made by using a Boehringer Mannheim cDNA 
synthesis kit (Boehringer Mannheim GmbH, Mannheim, Germany). Two 
micrograms of total RNA extracted from tissues and cultured cells were reverse 
transcribed using 10 μM random hexanucleotide primer, 1 mM dNTP, 8 mM 
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MgCl2, 30 mM KCl, 50 mM Tris·HCl, pH 8.5, 0.2 mM dithiothreithol, 25 U 
RNAse inhibitor, and 40 U AMV reverse transcriptase. The mixture was 
incubated at 30°C for 10 min and 42°C for 1 hr, followed by inactivation of the 
enzyme at 99°C for 5 min. 
 
7. Real-time PCR 
The primers used for aquaporin-3 (AQP3) and 18s amplification were as 
follows: AQP 3 sense 5′-AGCCCTGGATCAAGCTGCCC-3′, antisense 5′-
TTGGCA AAGGCCCAGATTG-3′; and 18s sense 5′-AGTCCCTGCCCT 
TTGTACACA-3′, antisense 5′- GATCCGAGGGCCTCACTAAAC-3′. cDNAs 
from 25 ng RNA of tissues and cultured cells per reaction tube were used for 
amplification. 
Using the ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems, Foster City, CA), PCR was performed with a total volume of 20 μl 
in each well, containing 10 μl of SYBR Green PCR Master Mix (Applied 
Biosystems), 5 μl of cDNA, and 5 pM sense and antisense primers. Primer 
concentrations were determined by preliminary experiments that analyzed the 
optimal concentrations of each primer. The PCR conditions were as follows: 35 
cycles of denaturation at 94.5°C for 30 sec, annealing at 60°C for 30 sec, and 
extension at 72°C for 1 min. Initial heating at 95°C for 9 min and final 
extension at 72°C for 7 min were performed for all PCR reactions. Each sample 
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was run in triplicate in separate tubes and a control without cDNA was also run 
in parallel with each assay. After real-time PCR, the temperature was increased 
from 60 to 95°C at a rate of 2°C/min to construct a melting curve. The cDNA 
content of each specimen was determined using a comparative CT method with 
2−ΔΔCT. The results are given as relative expression of AQP3 normalized to the 
expression of 18s rRNA and expressed in arbitrary units. Signals from C tissues 
and cells were assigned a relative value of 1.0. In pilot experiments, PCR 
products revealed a single band on agarose gels. 
 
8. Western blot analysis 
Pieces of tissues and harvested cultured cells were lysed in SDS sample 
buffer [2% SDS, 10 mM Tris·HCl, pH 6.8, 10% (vol/vol) glycerol], treated with 
Laemmli sample buffer, heated at 100°C for 5 min, and electrophoresed in an 
12% acrylamide denaturing SDS-polyacrylamide gel. Proteins were then 
transferred to a Hybond-ECL membrane using a Hoeffer semidry blotting 
apparatus (Hoeffer Instruments, San Francisco, CA), and the membrane was 
then incubated in blocking buffer A (1× PBS, 0.1% Tween 20, and 5% nonfat 
milk) for 1 hr at room temperature, followed by an overnight incubation at 4°C 
in a 1:1,000 dilution of polyclonal antibodies to AQP3, EGFP (Abcam, 
Cambridge, MA, USA), mCherry (GeneCopoeia, Germantown, MD, USA), or 
β-actin (Sigma-Aldrich, St. Louis, MO, USA). The membrane was then washed 
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once for 15 min and twice for 5 min in 1× PBS with 0.1% Tween 20. Next, the 
membrane was incubated in buffer A containing a 1:2,000 dilution of 
horseradish peroxidase-linked donkey anti-goat IgG (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA). The washes were repeated, and the membrane was 
developed with a chemiluminescent agent (ECL; Amersham Life Science, Inc., 
Arlington Heights, IL, USA). The band densities were measured using TINA 
image software (Raytest, Straubenhardt, Germany), and the changes in optical 
densities in the treated groups relative to C tissues or cells were used for 
analysis. 
 
9. Immunofluoresence staining 
For double-immunofluorescence staining, 4-μm frozen sections of the kidney, 
colon, and trachea were used. Slides were fixed in acetone for 10 min at 4°C, 
air-dried for 10 min, blocked with 10% donkey serum for 20 min, and incubated 
with a 1:1,000 dilution monoclonal antibody to EGFP (Abcam) for 3 hrs at 
room temperature. After washing, Cy2 (green)-conjugated anti-mouse IgG 
antibody (Research Diagnostics, Flanders, NJ, USA) was added for 60 min. A 
1:500 dilution of monoclonal rabbit anti-mCherry or polyclonal anti-AQP3 
(Abcam) was then applied, followed by Cy3 (red)-conjugated anti-rabbit IgG 
antibody or Cy2 (green)-conjugated anti-rabbit IgG antibody. 
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10. Urine volume and osmolality 
One or two days before killing mice, they were put in metabolic cages, and 
24-hr urine was collected. Urine volume was measured and osmolality was 
determined using a vapor pressure osmometer (5100C; Wescor, Logan, UT, 
USA). 
 
11. Statistical analysis 
All values are expressed as means ± standard errors of the mean (SEM). 
Statistical analyses were performed using the Statistical Package for Social 
Sciences for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL, USA). Results were 
analyzed using one-way ANOVA with a post hoc Bonferonni’s test for multiple 
comparisons. P values less than 0.05 were considered statistically significant. 
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III. RESULTS 
1. Gene-silencing efficiency 
 To verify whether LV-Hoxb7 Cre and LV-loxP shAQP3 generated for the 
current study can effectively silence AQP3 gene in mice, I first performed in 
vitro study using kidney collecting duct and mesangial cells. Effective 
transection of LV-Hoxb7 Cre and LV-loxP shAQP3 into cultured cells was 
confirmed by checking the protein expression of each virus-taq, mCherry and 
EGFP, respectively. As seen in Figure 2A, the protein expression of mCherry 
was demonstrated in cultured collecting duct cells treated with LV-Hoxb7 Cre 
or LV-Hoxb7 Cre + LV-loxP scr, while EGFP protein expression was observed 
in collecting duct cells exposed to LV-loxP shAQP3. In these cells, however, 
there was no significant change in the expression of AQP3 protein. Meanwhile, 
concomitant treatment LV-Hoxb7 Cre and LV-loxP shAQP3 significantly 
reduced the protein expression of AQP3 along with the presence of mCherry but 
not EGFP protein expression. The mRNA expression showed a similar pattern 
to the expression of each protein (Fig. 2B). In contrast to collecting duct cells, 
the protein expression of EGFP was found in mesangial cells treated with LV-
Hoxb7 Cre, LV-Hoxb7 Cre + LV-loxP scr, or LV-Hoxb7 Cre + LV-loxP shAQP3, 
while there was no mCherry protein expression in these cells. Moreover, the 
expression of AQP3 protein was comparable among the groups (Fig. 2C). These 
findings implied that LV-Hoxb7 Cre, which contained Hoxb7 promoter, worked 
 21 
 
only in collecting duct cells due to the presence of Hoxb7 in collecting duct 
cells but not in mesangial cells. Furthermore, combined infection of collecting 
duct cells with LV-Hoxb7 Cre and LV-loxP shAQP3 significantly inhibited the 
protein expression of AQP3 along with the disappearance of EGFP protein 
expression, suggesting that LV-Hoxb7 Cre and LV-loxP shAQP3 used in the 
present study worked together effectively.  
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Figure 2. A representative Western blot of EGFP, mCherry, and β-actin in 
collecting duct cells (A) and mesangial cells (C) treated with PBS (Con), LV-Hoxb7 
Cre, LV-loxP shAQP3, LV-Hoxb7 Cre + LV-loxP scr, or LV-Hobx7 Cre + LV-
loxP shAQP3 (representative of four blots). (B) Real-time PCR for AQP3 in these 
five groups. 
*; p < 0.0001 vs. Con
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2. In vivo transduction efficiency 
 Next, animal experiments were performed to test in vivo transduction 
efficiency. Hydrodynamic tail vein injection of PBS (Con), LV-Hoxb7 Cre, LV-
loxP scr, or LV-loxP shAQP3 was done to twelve C57BL/6J mice thrice with a 
3-4 days interval (n=4 per group). Semi-nested PCR revealed that EGFP 
expression was the highest in the liver and spleen, kidney at 6-week after the 
first injection, but mCherry expression was found only in the kidney (Fig. 3A). 
In addition, immunofluorescence staining demonstrated that EGFP protein was 
significantly expressed in all tissues of LV-injected mice but not in those of 
PBS-injected mice at 6-week.  The expression of mCherry protein was found 
only in the kidney collecting duct cells (Fig. 3B).  
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Figure 3. Distribution and transduction efficiencies of hydrodynamically injected 
lentiviral vectors. (A) A representative semi-nested PCR for EGFP and mCherry. EGFP 
expression was observed in the liver, spleen, kidney, colon, and trachea, but mCherry 
expression was found only in the kidney. (B) A representative immunofluorescence 
staining for EGFP and mCherry. EGFP protein was strongly expressed in the kidney of 
lentivirus-injected mice at 6-week after the first lentiviral injection. In contrast, mCherry 
protein was expressed only in the kidney collecting duct cells (x 200).
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3. Animal data of loxP-EGFP mice injected with LV-Hoxb7 Cre 
loxP-EGFP mice, which express EGFP in the presence of Cre recombinase, 
were treated with LV-Hoxb7 Cre via hydrodynamic tail vein injection. As seen 
in Figure 4A, both EGFP and mCherry protein expression were found only in 
the kidney, where Hoxb7 promoter was working, but not in the liver of loxP-
EGFP + LV-Hoxb7 Cre mice. Immunofluorescence staining also confirmed that 
EGFP and mCherry protein were completely expressed at the same site, kidney 
collecting duct cells (Fig. 4B). 
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Figure 4. EGFP and mCherry protein expression in loxP-EGFP mice injected with 
LV-Hoxb7 Cre. (A) Western blot analysis revealed that both EGFP and mCherry 
protein expression were found only in the kidney, but not in the liver of LoxP-EGFP + 
LV-Hoxb7 Cre mice. (B) Both EGFP and mCherry protein, assessed by 
immunofluorescence staining, were completely expressed at the same site, kidney 
collecting duct cells (x 400).
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4. Animal data of Hoxb7 Cre mice injected with LV-loxP shAQP3 
Hoxb7 Cre mice, which express Cre recombinase only in kidney collecting 
duct cells, were administered with LV-loxP shAQP3 via hydrodynamic tail vein 
injection. As seen in Figure 5A, the protein expression of EGFP in the kidney 
was observed in Hoxb7 Cre mice injected with LV-loxP scr or LV-loxP shAQP3. 
Furthermore, AQP3 protein and mRNA expression, assessed by Western blot, 
immunofluorescence staining and nested real-time PCR, were significantly 
reduced in Hoxb7 Cre + LV-loxP shAQP3 mice compared to Hoxb7 Cre + PBS 
and Hoxb7 Cre + LV-loxP scr mice (Fig. 5A-5C). In addition, while urine 
volume was significantly increased, urine osmolality was significantly 
decreased by 44.4% in Hoxb7 Cre + LV-loxP shAQP3 mice compared to the 
other groups (Fig. 5D). 
In contrast, there was no significant change in the protein expression of 
AQP3 in the colon and trachea by LV-loxP scr or LV-loxP shAQP3 injection in 
spite of demonstrable expression of EGFP protein, denoting that LV-loxP 
shAQP3 had no effects on AQP3 protein expression in the tissues where Hoxb7 
protein did not exist (Fig. 6). 
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Figure 5. EGFP and AQP3 expression in the kidney, and urine volume and 
osmolality in Hoxb7 Cre mice injected with LV-loxP shAQP3. (A) Western blot 
analysis revealed that the protein expression of EGFP in the kidney was observed in 
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Hoxb7 Cre mice injected with LV-loxP scr or LV-loxP shAQP3. In addition, AQP3 
protein expression was significantly reduced in Hoxb7 Cre + LV-loxP shAQP3 mice 
compared to Hoxb7 Cre + PBS and Hoxb7 Cre + LV-loxP scr mice. (B) AQP3 mRNA 
expression, assessed by nested real-time PCR, was also significantly reduced in Hoxb7 
Cre + LV-loxP shAQP3 mice. (C) Double-immunofluorescence staining showed that 
EGFP protein (green) expression within the kidney was observed in all cells except for 
the collecting duct cells in Hoxb7 Cre mice injected with LV-loxP scr or LV-loxP 
shAQP3. Moreover, the expression of AQP3 protein (red) was significantly decreased in 
the collecting duct cells in LV-loxP shAQP3-injected mice, while LV-loxP scr had no 
effect on the protein expression of AQP3 (x 400). (D) While urine volume was 
significantly increased, urine osmolality was significantly decreased by 44.4% in Hoxb7 
Cre + LV-loxP shAQP3 mice compared to the other groups. 
#; p < 0.001 vs. Con, *; p < 0.0001 vs. Con
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Figure 6. EGFP and AQP3 expression in the colon and trachea of Hoxb7 Cre mice 
injected with LV-loxP shAQP3. There were no significant changes in AQP3 protein 
and mRNA expression in the colon and trachea of Hoxb7 Cre mice injected with LV-
loxP scr or LV-loxP shAQP3 in spite of demonstrable expression of EGFP protein. 
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5. Animal data of C57BL/6J mice treated with consecutive injection of LV-
Hoxb7 Cre and LV-loxP shAQP3 
 Finally, I tried to generate AQP3 knockout mice in C57BL/6J mice by 
consecutive injection of LV-Hoxb7 Cre and LV-loxP shAQP3. When LV-Hoxb7 
Cre was introduced in these mice, the expression of mCherry protein was found 
only in the kidney collecting duct cells. Moreover, injection of LV-loxP shAQP3 
resulted in an increase in EGFP protein expression in all kidney cells except for 
collecting duct cells. However, there were no significant differences in the 
protein and mRNA expression of AQP3, urine volume, and urine osmolality in 
C57BL/6J mice injected with LV-Hoxb7 Cre or LV-loxP shAQP3 alone (Fig. 7). 
In contrast, when consecutive injection of LV-Hoxb7 Cre and LV-loxP AQP3 
was performed in these mice, AQP3 protein and mRNA expression were 
significantly reduced along with a significant increase in urine volume and a 
significant decrease in urine osmolality (Fig. 7). 
Meanwhile, the protein expression of EGFP was also observed in the colon 
and trachea of C57BL/6J mice by the administration of LV-loxP shAQP3 with 
or without LV-Hoxb7 Cre, but AQP3 protein expression was not changed by 
these treatment (Fig. 8). 
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Figure 7. EGFP, mCherry, and AQP3 expression in the kidney, and urine volume 
and osmolality in C57BL/6J mice treated with consecutive injection of LV-Hoxb7 
Cre and LV-loxP shAQP3. (A) Western blot analysis revealed that the protein 
expression of EGFP in the kidney was observed in C57BL/6J injected with LV-loxP 
shAQP3 or LV-Hoxb7 Cre + LV-loxP shAQP3, while the expression of mCherry protein 
was found in the kidney of LV-Hoxb7 Cre or LV-Hoxb7 Cre + LV-loxP shAQP3 mice. 
In addition, AQP3 protein expression was significantly reduced in C57BL/6J mice 
injected with LV-Hoxb7 Cre + LV-loxP shAQP3 compared to mice treated with LV-
 37 
 
Hoxb7 Cre or LV-loxP shAQP3 alone. (B) AQP3 mRNA expression, assessed by nested 
real-time PCR, was also significantly reduced in Hoxb7 Cre + LV-loxP shAQP3 mice. 
(C) Double-immunofluorescence staining showed that EGFP protein (green) expression 
within the kidney was observed in C57BL/6J injected with LV-loxP shAQP3 or LV-
Hoxb7 Cre + LV-loxP shAQP3 in all cells except for the collecting duct cells, while the 
expression of mCherry protein was found only in the kidney collecting duct cells of LV-
Hoxb7 Cre or LV-Hoxb7 Cre + LV-loxP shAQP3 mice. Moreover, the expression of 
AQP3 protein was significantly decreased in the collecting duct cells in C57BL/6J mice 
injected with LV-Hoxb7 Cre + LV-loxP shAQP3 (x 400). (D) While urine volume was 
significantly increased, urine osmolality was significantly decreased in LV-Hoxb7 Cre + 
LV-loxP shAQP3 mice compared to the other groups. 
#; p < 0.001 vs. Con, *; p < 0.0001 vs. Con
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Figure 8. EGFP and AQP3 expression in the colon and trachea of C57BL/6J mice 
treated with consecutive injection of LV-Hoxb7 Cre and LV-loxP shAQP3. There 
were no significant changes in AQP3 protein and mRNA expression in the colon and 
trachea of C57BL/6J mice injected with LV-Hoxb7 Cre and LV-loxP shAQP3 in spite of 
demonstrable expression of EGFP protein. 
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IV. DISCUSSION 
In this study, injection of LV-loxP shAQP3 to Hoxb7 Cre mice significantly 
reduced AQP3 expression along with a significant increase in urine volume and 
a significant decrease in urine osmolality. Similar findings were observed in 
C57BL/6J mice with a consecutive introduction of LV-Hoxb7 Cre and LV-loxP 
shAQP3. In contrast, there were no changes in AQP3 expression in the colon 
and trachea of these mice. These findings suggest that double transduction of 
Cre- and loxP-based lentivirus can be a simple way to generate cell-specific 
knockdown mice, and this method may also be applicable to other species. 
Since the first transgenic mice were generated in 198019-22, genetically 
engineered transgenic and knockout mice have become exceptionally valuable 
experimental models to assess the role of a specific gene in not only the 
development and organogenesis but also the pathogenesis of a certain 
disease1,23,24. However, conventional transgenic and knockout techniques had 
some limitations. Specifically, conventional knockout method using oocytes or 
ES cells can result in an embryonic or perinatal phenotype if the manipulated 
gene is essential for the development or organogenesis. Sterile mice can also be 
generated. In addition, since the function of the gene of interest can be disparate 
in diverse tissues and cells as well as at different developmental stages, deletion 
of this gene in the whole body throughout mice ontogeny can make it hard or 
impossible to understand its precise function in a specific tissue. Moreover, 
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compensatory overexpression of other genes can be accompanied. 
To overcome these limitations, the second generation of genetically engineer 
knockout mice was developed. Of these mice, namely conditional knockout 
mice, tissue-specific knockout mice were generated using a tissue-specific 
promoter and site-specific recombinase systems (SSR) such as Cre-loxP, Flp-
FRT, and ΦC31 systems. Among these SSR, the Cre-loxP system has been the 
most widely used system both in vitro and in vivo25-29, Furthermore, a 
combination of this Cre-loxP system with inducible systems, such as 
tetracycline9,30-32 and tamoxifen-inducible systems33, made it possible to 
generate tissue- and stage-specific conditional knockout mice. Nevertheless, 
this procedure is still difficult and time-consuming. It needs to spend several 
years of work, and sometimes in vain. In addition, the cost for making a 
transgenic animal have reduced with advances in biotechnology, it still needs a 
huge amount of money. Moreover, this technique is not easily applicable to 
other species. Therefore, an easier and simpler way to generate tissue- or cell-
specific knockout mice at any developmental stage is keenly necessary. In the 
current study, renal collecting duct cell-specific AQP3 knockdown mice was 
simply generated mainly based on the Cre-loxP system. Furthermore, based on 
the preliminary results showing that injection of LV-Hoxb7 Cre to loxP-EGFP 
mice via tail vein thrice at 3-4 days intervals resulted in significantly higher 
transfection efficiency compared to single or twice injection (data not shown), it 
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is inferred that the magnitude of AQP3 knockdown in the collecting tubule can 
be regulated or even knockout can be accomplished by modifying the number 
of times and the dose of LV-shAQP3 injection. 
For AQP3 shRNA delivery, lentiviral vector was used in the present study. 
Various viruses such as retrovirus, adenovirus, and lentivirus, and plasmid 
vectors that are DNA itself, have been used for gene transfer. Among these, 
lentivirus-based gene delivery system has several advantages; genes are 
incorporated into host chromosomes and continuously expressed for a long time, 
therefore able to maintain long-term treatment efficiency34. In addition, genes 
can be effectively conveyed to differentiated and non-dividing cells such as 
nerve cells, while ordinary retrovirus does not35-37. Recently, moreover, 
transgenic animals were successfully generated by infecting siRNA or shRNA 
into zygotes or ES cells via lentivirus-based vector38-41. Collectively, lentivirus 
has been widely employed to manipulate gene in mammalian cells both in vitro 
and in vivo. The results of my study also showed that lentivirus-based delivery 
of Hoxb7 Cre and/or AQP3 shRNA was effectively incorporated in renal 
collecting duct cells, and the transfer effect lasted for up to 3 months (data not 
shown). 
On the other hand, previous studies have demonstrated several undesirable 
effects of shRNA transduction, including induction of interferon response, off-
target gene effects, and hepatotoxicity with increased mortality. Regarding 
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hepatotoxicity, Grimm et al42 found a significantly high incidence of mortality 
due to a dose-dependent liver injury, which was attributed to the saturation of 
nuclear karyopherin exportin-5 and downregulation of liver-derived 
microRNAs (miRNAs). Based on these findings, they suggested this risk can be 
minimized by optimizing shRNA dose and sequence. In this study, LV-AQP3 
shRNA were injected three times, but the dose of one injection was 4 × 108 TU, 
which was determined based on the results of our previous study. It was 
significantly less compared to the previous study by Grimm et al42. Furthermore, 
the size of shRNA was 19-mer, the same size associated with the least toxicity 
in that study. In addition, the shRNA used in the current study was design to 
exert its effect only in the kidney. These may be the reason why I did not 
observe any serious side effects of in vivo shRNA transduction. Nevertheless, 
the possibility of similar consequences of oversaturated shRNA in the kidney as 
in the liver cannot be completely excluded. 
To deliver gene or shRNA in a specific organ, the route of administration is 
an important issue. Specifically for the kidney, even though several invasive 
delivery techniques43-46; via renal artery, renal vein, and ureter, and direct 
parenchymal injection, have been developed and used in small rodents, 
hydrodynamic tail vein47 delivery has recently been regarded as a simple and 
effective method for gene transfer into these animals. A previous study by 
Kobayashi et al48-50 showed that intravenous injection of pU6-stem21, a model 
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of siRNA-expressing vector, by the hydrodynamics-based procedure resulted in 
significant suppression of the target transgene expression in the liver, kidney, 
and lung. Another previous study also demonstrated that hydrodynamic tail vein 
delivery of gene successfully changed the levels of transgene expression in the 
kidney and lung, even though their expression levels were approximately one-
sixth to one-fifth of those in the liver. Based on these findings, a simple 
hydrodynamic tail vein injection of lentiviral vector was performed in the 
present study. Instead the number of injection time was increased to delivery 
more effectively to the kidney. As a result, LV-shAQP3 delivery, assessed by 
EGFP protein expression, was successful and sufficient in not only the kidney 
but also the colon and trachea. 
Because of my main interest in kidney disease, the gene of interest selected to 
knockdown in this study was AQP3. The gene of interest was assumed to be the 
best if the presenting phenotype with deleted gene can be easily recognized by a 
simple test or assessment of blood or urine even before killing the mice. At the 
first time, therefore, AQP1 was selected for the candidate gene to be deleted. 
However, since the distribution of AQP1 was exclusively confined to the kidney 
(with scanty expression in the testis)51, it was difficult to discriminate collecting 
duct cell-specific knockdown from non-specific knockdown. Accordingly, 
AQP3 was finally chosen based on the fact that AQP3 knockout mice also had 
polyuria and impairment of urinary concentrating52 ability as AQP1 knockout 
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mice and that AQP3 was widely expressed in the body53, including the colon, 
trachea, brain54, and eye55. The results of the current study revealed that LV-
shAQP3 injection to Hoxb7 Cre mice and consecutive injection of LV-Hoxb7 
Cre and LV-shAQP3 knocked down AQP3 expression in the collecting duct 
cells of the kidney along with a significant increase in urine volume and a 
significant decrease in urine osmolality, while there was no changes in the 
expression of AQP3 in the colon and trachea, suggesting that this method 
successfully generated and could be a simple way to generate cell-specific 
knockdown mice. 
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V. CONCLUSION 
In this study, introduction of LV-loxP shAQP3 to Hoxb7 Cre mice or 
consecutive injection of LV-Hoxb7 Cre and LV-loxP shAQP3 in C57BL/6J mice 
significantly reduced AQP3 protein and mRNA expression along with 
significant changes in urine volume and osmolality. In contrast, there were no 
changes in AQP3 protein and mRNA expression in the colon and trachea of 
these mice. These findings suggest that double transduction of Cre- and loxP-
based lentivirus can be a simple way to generate cell-specific knockdown mice, 
and this method may also be applicable to other species. 
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ABSTRACT (IN KOREAN) 
 
Cre/loxP lentiviral vector 이중 형질주입을 이용한 
세포-특이적 녹다운 마우스의 제작 
 
<지도교수 강신욱> 
 
연세대학교 대학원 의과학과 
 
남 보 영 
 
배경: 유전자의 생체 내 기능을 정확하게 규명하기 위해서는 특정 
유전자 조작을 통하여 개발된 형질전환 동물의 이용이 유용하다. 
그러나, 생명 유지에 필수적인 유전자를 조작하였을 때 실험 동물이 
사망할 수 있을 뿐만 아니라, 영구적인 전신적 유전자 조작에 따른 
모든 조직에서의 영향과 다른 유전자의 활성화 또는 불활성화, 
그리고 성인에서 발생하는 질병에서의 유전자의 기능을 규명하는 
것이 제한적이라는 등의 문제점이 있을 수 있다. 최근에는 이러한 
문제의 극복을 위하여 조직-특이적, 세포-특이적 유전자 조작 기술이 
개발되어 질환에 따른 각각의 조직 및 세포에서의 유전자 기능을 
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규명하는데 큰 도움이 되고 있다. 이러한 세포-특이적 유전자 조작의 
방법으로는 Cre/loxP 시스템과 Tet-on/off 시스템들이 이용되고 있으나, 
이들 방법은 embryonic stem cell에 세포-특이적 Cre 유전자와 loxP 
유전자를 주입한 후 수정과 교배 과정을 거쳐 유전자 재조합 동물을 
제작하게 되기 때문에 시간적뿐만 아니라 경제적인 문제로 이용이 
제한적이라는 단점이 있다. 또한, 이들 방법 역시 위에서 언급하였던 
문제점들을 완벽하게 해결해 주지는 못하고 있다. 
 
목적: 본 연구에서는 Cre/loxP 시스템과 lentiviral vector를 이용하여 
조건부 시기에, 그리고 특이 세포 및 조직에서만 유전자가 조작될 수 
있는 동물 모델 시스템을 개발하고자 한다. 
 
방법: 생체 외 실험으로는 집합관 세포와 메산지움 세포를 Hoxb7-Cre 
lentivirus (LV-Hoxb7-Cre)와 아쿠아포린-3 (AQP3)에 대한 shRNA를 
포함한 loxP-shAQP3 lentivirus (LV-loxP shAQP3)로 처리하고 72시간 후 
각 군에서 세포를 수집하였다. 생체 내 실험으로는 각각의 
바이러스의 효과를 확인하기 위하여 3가지의 동물 모델을 대상으로 
실험하였다. 첫째로, loxP-EGFP 마우스에 LV-Hoxb7 Cre를 주입하여 
Hoxb7 프로모터의 효과를 확인하였다. 둘째로, Hoxb7 Cre 마우스에 
 55 
 
LV-loxP scr과 LV-loxP shAQP3를 주입하여 loxP-shAQP3의 효과를 
확인하였다. 셋째로, C57BL6/J 마우스에 LV-Hoxb7 Cre와 LV-loxP 
shAQP3를 각각 투여한 군들과 LV-Hoxb7 Cre + LV-loxP shAQP3 동시에 
투여한 군으로 나누어 그 효과를 관찰하였다. 모든 동물들은 5일 
간격으로 3회에 걸쳐 1ml의 phosphate-buffered saline 또는 lentivirus를 
꼬리정맥 내로 주사하였다. 마지막 주사 후 4주째에 24시간 소변을 
채취하고 동물을 희생하여 조직을 채취하였다. 각각의 세포와 
마우스의 조직 내에서 EGFP, mCherry, 그리고 AQP3의 단백 발현은 
Western blot과 면역형광염색방법을 이용하여 분석하였고, AQP3의 
mRNA 발현은 Real-time PCR로 평가하였다. 24시간 동안 채취한 
동물의 소변 양과 삼투질 농도도 측정하였다. 
 
결과: 메산지움 배양세포를 각각의 바이러스로 처리하였을 때 LV-loxP 
shAQP3 처리군에서는 EGFP의 발현이 확인되었으나, LV-Hoxb7 Cre 
처리군에서는 mCherry의 발현이 확인되지 않았다. 반면, 집합관 
배양세포에서는 LV-loxP shAQP3 처리군에서의 EGFP와 LV-Hoxb7 Cre 
군에서의 mCherry 모두가 발현되었으며, LV-Hoxb7 Cre + LV-loxP 
shAQP3 처리군에서만 AQP3의 발현 감소를 확인함으로써 Hoxb7 
프로모터가 신장 집합관 세포에서만 작동함과 동시에 생체 외 
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실험에서 shAQP3의 효과를 규명하였다. 생체 내 첫 번째 실험에서는 
EGFP-loxP 마우스에 LV-Hoxb7 Cre를 투여한 군에서 mCherry와 
EGFP가 동일한 부분, 즉 신장 집합관 세포에서 발현되는 것을 
관찰함으로써 마우스 생체 내에서 Hoxb7 프로모터의 작동을 
확인하였다. 두 번째 실험인 Hoxb7 Cre 형질전환 마우스를 이용한 
실험에서는 LV-loxP shAQP3를 투여한 군에서의 AQP3의 mRNA와 
단백 발현이 대조군 및 LV-loxP scr 투여군에 비하여 의미있게 
감소됨을 확인하였다. 또한, LV-loxP shAQP3 투여군에서 24시간 소변 
양은 의의있게 증가되었으며, 24시간 소변 내 삼투질 농도는 유의하게 
감소되었다. 이와는 반대로, 대장과 기도 조직 내에서의 AQP3 발현은 
각 군간에 차이가 없었다. 마지막으로, C57BL/6J 마우스를 이용한 
실험에서는 LV-loxP shAQP3를 투여한 군에서는 신장 집합관 세포를 
포함한 모든 세포에서 EGFP가 발현되었던 반면, LV-Hoxb7 Cre를 
투여한 군에서는 신장 집합관 세포에서만 mCherry가 발현되었다. LV-
Hoxb7 Cre + LV-loxP shAQP3를 동시에 투여한 군에서는 신장 집합관 
세포에서만 mCherry가 발현되었으며, 신장 집합관 세포를 제외한 
모든 세포에서 EGFP 발현이 확인되었고, 신장 집합관 세포에서의 
AQP3 단백 발현 역시 대조군을 비롯한 다른 군들과 비교하였을 때 
의미있게 감소되었다. 또한, LV-Hoxb7 Cre + LV-loxP shAQP3 군에서의 
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24시간 소변 양은 다른 군에 비하여 의의있게 증가되었으며, 24시간 
소변 내 삼투질 농도는 유의하게 감소되었다. 그러나, AQP3가 
발현되는 다른 장기인 대장과 기도 조직에서는 EGFP만이 발현되고 
mCherry가 발현되지 않았으며, AQP3의 발현도 각 군간에 차이가 
없었다. 
 
결론: Lentiviral vector를 기반으로 한 Cre/loxP 시스템을 이용할 경우 
매우 간단하게 세포-특이적 녹다운 마우스 모델을 제작할 수 있을 
것으로 생각되며, 이러한 방법은 다른 종에도 적용이 가능할 것으로 
사료된다. 
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